Structure-activity relationships of a small-molecule inhibitor of the PDZ domain of PICK1.

Recently, we described the first small-molecule inhibitor, (E)-ethyl 2-cyano-3-(3,4-dichlorophenyl)acryloylcarbamate (1), of the PDZ domain of protein interacting with Calpha-kinase 1 (PICK1), a potential drug target against brain ischemia, pain and cocaine addiction. Herein, we explore structure-activity relationships of 1 by introducing subtle modifications of the acryloylcarbamate scaffold and variations of the substituents on this scaffold. The configuration around the double bond of 1 and analogues was settled by a combination of X-ray crystallography, NMR and density functional theory calculations. Thereby, docking studies were used to correlate biological affinities with structural considerations for ligand-protein interactions. The most potent analogue obtained in this study showed an improvement in affinity compared to 1 and is currently a lead in further studies of PICK1 inhibition.

[1]  Y. Jan,et al.  Clustering of Shaker-type K+ channels by interaction with a family of membrane-associated guanylate kinases , 1995, Nature.

[2]  Harel Weinstein,et al.  Identification of a small-molecule inhibitor of the PICK1 PDZ domain that inhibits hippocampal LTP and LTD , 2009, Proceedings of the National Academy of Sciences.

[3]  G. G. Stokes.  "J." , 1890, The New Yale Book of Quotations.

[4]  P. Seeburg,et al.  Domain interaction between NMDA receptor subunits and the postsynaptic density protein PSD-95. , 1995, Science.

[5]  Yitao Liu,et al.  Treatment of Ischemic Brain Damage by Perturbing NMDA Receptor- PSD-95 Protein Interactions , 2002, Science.

[6]  M. Lazdunski,et al.  Protein Kinase C Stimulates the Acid-sensing Ion Channel ASIC2a via the PDZ Domain-containing Protein PICK1* , 2002, The Journal of Biological Chemistry.

[7]  P. Kočovský.  Carbamates : A method of synthesis and some syntehtic applications , 1986 .

[8]  Wendell A. Lim,et al.  β Strand Peptidomimetics as Potent PDZ Domain Ligands , 2006 .

[9]  R. Huganir,et al.  Clustering of AMPA Receptors by the Synaptic PDZ Domain–Containing Protein PICK1 , 1999, Neuron.

[10]  Harvey T. McMahon,et al.  Membrane curvature and mechanisms of dynamic cell membrane remodelling , 2005, Nature.

[11]  Christopher L. McClendon,et al.  Reaching for high-hanging fruit in drug discovery at protein–protein interfaces , 2007, Nature.

[12]  R. Giles,et al.  Regiospecific Reduction of 5-Benzylidene-2,4-Thiazolidinediones and 4-Oxo-2-thiazolidinethiones using Lithium Borohydride in Pyridine and Tetrahydrofuran , 2000 .

[13]  J. Topliss,et al.  A manual method for applying the Hansch approach to drug design. , 1977, Journal of medicinal chemistry.

[14]  John H. Lewis,et al.  Crystal Structures of a Complexed and Peptide-Free Membrane Protein–Binding Domain: Molecular Basis of Peptide Recognition by PDZ , 1996, Cell.

[15]  S. Fleetwood-Walker,et al.  Specific involvement in neuropathic pain of AMPA receptors and adapter proteins for the GluR2 subunit , 2003, Molecular and Cellular Neuroscience.

[16]  Jufang Shan,et al.  Optimizing Dvl PDZ domain inhibitor by exploring chemical space , 2009, J. Comput. Aided Mol. Des..

[17]  W. Dunn,et al.  Examination of the utility of the Topliss schemes for analog synthesis. , 1973, Journal of medicinal chemistry.

[18]  J Staudinger,et al.  PICK1: a perinuclear binding protein and substrate for protein kinase C isolated by the yeast two-hybrid system , 1995, The Journal of cell biology.

[19]  D. Bashford,et al.  Rational design of the first small-molecule antagonists of NHERF1/EBP50 PDZ domains. , 2008, Bioorganic & medicinal chemistry letters.

[20]  Louis J. Farrugia,et al.  ORTEP-3 for Windows - a version of ORTEP-III with a Graphical User Interface (GUI) , 1997 .

[21]  R. Henry,et al.  Discovery and metabolic stabilization of potent and selective 2-amino-N-(adamant-2-yl) acetamide 11beta-hydroxysteroid dehydrogenase type 1 inhibitors. , 2007, Journal of medicinal chemistry.

[22]  W. Delano.  The PyMOL Molecular Graphics System , 2002 .

[23]  T. Hahn.  International tables for crystallography , 2002 .

[24]  J. Henley,et al.  PICK1 is a calcium‐sensor for NMDA‐induced AMPA receptor trafficking , 2005, The EMBO journal.

[25]  P. Hajduk,et al.  Druggability indices for protein targets derived from NMR-based screening data. , 2005, Journal of medicinal chemistry.

[26]  Harel Weinstein,et al.  Membrane Localization is Critical for Activation of the PICK1 BAR Domain , 2008, Traffic.

[27]  Jie J. Zheng,et al.  Sulindac inhibits canonical Wnt signaling by blocking the PDZ domain of the protein Dishevelled. , 2009, Angewandte Chemie.

[28]  U. Haupts,et al.  Homogeneous fluorescence readouts for miniaturized high-throughput screening: theory and practice. , 1999, Drug discovery today.

[29]  D. Doyle,et al.  Structure of PICK1 and other PDZ domains obtained with the help of self‐binding C‐terminal extensions , 2007, Protein science : a publication of the Protein Society.

[30]  R. Neubig,et al.  Small Molecule Protein–Protein Interaction Inhibitors as CNS Therapeutic Agents: Current Progress and Future Hurdles , 2009, Neuropsychopharmacology.

[31]  J. Owicki,et al.  Fluorescence Polarization and Anisotropy in High Throughput Screening: Perspectives and Primer , 2000, Journal of biomolecular screening.

[32]  Jie J. Zheng,et al.  Discovery and Characterization of a Small Molecule Inhibitor of the PDZ Domain of Dishevelled* , 2009, The Journal of Biological Chemistry.

[33]  M. Potashman,et al.  Covalent modifiers: an orthogonal approach to drug design. , 2009, Journal of medicinal chemistry.

[34]  Stephen A. Smith,et al.  [[omega-(Heterocyclylamino)alkoxy]benzyl]-2,4-thiazolidinediones as potent antihyperglycemic agents. , 1994, Journal of medicinal chemistry.

[35]  L. Cantley,et al.  Recognition of Unique Carboxyl-Terminal Motifs by Distinct PDZ Domains , 1997, Science.

[36]  Michelle R. Arkin,et al.  Small-molecule inhibitors of protein–protein interactions: progressing towards the dream , 2004, Nature Reviews Drug Discovery.

[37]  K. Dev,et al.  Making protein interactions druggable: targeting PDZ domains , 2004, Nature Reviews Drug Discovery.

[38]  A. Levey,et al.  Functional Interaction between Monoamine Plasma Membrane Transporters and the Synaptic PDZ Domain–Containing Protein PICK1 , 2001, Neuron.

[39]  Ar Lang,et al.  International Tables for Crystallography, Vol C , 1992 .

[40]  P. Schmieder,et al.  Discovery of low-molecular-weight ligands for the AF6 PDZ domain. , 2006, Angewandte Chemie.

[41]  P. Jemth,et al.  Modified peptides as potent inhibitors of the postsynaptic density-95/N-methyl-D-aspartate receptor interaction. , 2008, Journal of medicinal chemistry.

[42]  H. Weinstein,et al.  Molecular Determinants for the Complex Binding Specificity of the PDZ Domain in PICK1* , 2005, Journal of Biological Chemistry.

[43]  E. Park,et al.  PICK1-mediated GluR2 endocytosis contributes to cellular injury after neuronal trauma , 2009, Cell Death and Differentiation.

[44]  M. Houslay.  Disrupting specific PDZ domain‐mediated interactions for therapeutic benefit , 2009, British journal of pharmacology.

[45]  P. Jemth,et al.  Two Conserved Residues Govern the Salt and pH Dependencies of the Binding Reaction of a PDZ Domain* , 2006, Journal of Biological Chemistry.

[46]  R. Huganir,et al.  Calcium-Permeable AMPA Receptor Plasticity Is Mediated by Subunit-Specific Interactions with PICK1 and NSF , 2005, Neuron.

[47]  Chi-Ying F. Huang,et al.  PICK1, an Anchoring Protein That Specifically Targets Protein Kinase Cα to Mitochondria Selectively upon Serum Stimulation in NIH 3T3 Cells* , 2003, Journal of Biological Chemistry.

[48]  A. Doherty,et al.  Structure-activity relationships in a series of orally active gamma-hydroxy butenolide endothelin antagonists. , 1997, Journal of medicinal chemistry.

[49]  Andrea Piserchio,et al.  Targeting specific PDZ domains of PSD-95; structural basis for enhanced affinity and enzymatic stability of a cyclic peptide. , 2004, Chemistry & biology.

[50]  K. Dev,et al.  PDZ domain protein-protein interactions: a case study with PICK1. , 2007, Current topics in medicinal chemistry.

[51]  Lauren G. Umek,et al.  Novel Copolymers of Trisubstituted Ethylenes and Styrene. II. Halogen Ring‐Substituted Ethyl 2‐Cyano‐1‐oxo‐3‐phenyl‐2‐propenylcarbamates , 2004 .

[52]  Sudhir C. Sharma,et al.  A Chemical Library Approach to Organic‐Modified Peptide Ligands for PDZ Domain Proteins: A Synthetic, Thermodynamic and Structural Investigation , 2008, Chembiochem : a European journal of chemical biology.

[53]  R. Huganir,et al.  Cerebellar Long-Term Depression Requires PKC-Regulated Interactions between GluR2/3 and PDZ Domain–Containing Proteins , 2000, Neuron.

[54]  Pavel Osten,et al.  PICK1 Targets Activated Protein Kinase Cα to AMPA Receptor Clusters in Spines of Hippocampal Neurons and Reduces Surface Levels of the AMPA-Type Glutamate Receptor Subunit 2 , 2001, The Journal of Neuroscience.

[55]  L. Vassilev,et al.  Targeting protein–protein interactions for cancer therapy , 2005, Journal of Molecular Medicine.

[56]  C. Lüscher,et al.  Cocaine triggered AMPA receptor redistribution is reversed in vivo by mGluR-dependent long-term depression , 2006, Nature Neuroscience.

[57]  B. Peter,et al.  BAR Domains as Sensors of Membrane Curvature: The Amphiphysin BAR Structure , 2004, Science.

[58]  M. Sheng,et al.  PDZ Domains: Structural Modules for Protein Complex Assembly* , 2002, The Journal of Biological Chemistry.

[59]  Irwin D Kuntz,et al.  A selective irreversible inhibitor targeting a PDZ protein interaction domain. , 2003, Journal of the American Chemical Society.

[60]  Irwin D Kuntz,et al.  Rational design of a nonpeptide general chemical scaffold for reversible inhibition of PDZ domain interactions. , 2007, Bioorganic & medicinal chemistry letters.

[61]  George Khelashvili,et al.  Modeling membrane deformations and lipid demixing upon protein-membrane interaction: the BAR dimer adsorption. , 2009, Biophysical journal.

[62]  M. Sheng,et al.  PDZ domain proteins of synapses , 2004, Nature Reviews Neuroscience.

[63]  J. Mellor,et al.  PICK1-mediated Glutamate Receptor Subunit 2 (GluR2) Trafficking Contributes to Cell Death in Oxygen/Glucose-deprived Hippocampal Neurons* , 2009, Journal of Biological Chemistry.

[64]  D. Earnshaw,et al.  Real Experiences of uHTS: A Prototypic 1536-Well Fluorescence Anisotropy-Based uHTS Screen and Application of Well-Level Quality Control Procedures , 2001, Journal of biomolecular screening.

[65]  Young Ho Suh,et al.  An Essential Role for PICK1 in NMDA Receptor-Dependent Bidirectional Synaptic Plasticity , 2008, Neuron.

[66]  S. Nakanishi,et al.  PICK1 Interacts with and Regulates PKC Phosphorylation of mGLUR7 , 2000, The Journal of Neuroscience.

[67]  J. Topliss,et al.  Utilization of operational schemes for analog synthesis in drug design. , 1972, Journal of medicinal chemistry.

[68]  L. Olsen,et al.  Design and synthesis of highly potent and plasma-stable dimeric inhibitors of the PSD-95-NMDA receptor interaction. , 2009, Angewandte Chemie.

[69]  G. Collingridge,et al.  PDZ Proteins Interacting with C-Terminal GluR2/3 Are Involved in a PKC-Dependent Regulation of AMPA Receptors at Hippocampal Synapses , 2000, Neuron.